[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2019 - January 1920

Decade

Year

Issue

June 2015, Vol 151, No. 6, Pages 577-692

In This Issue of JAMA Dermatology

Highlights

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):577. doi:10.1001/jamadermatol.2014.2921
Viewpoint

In Search of a Proportionate Funding in Medicine

Abstract Full Text
JAMA Dermatol. 2015;151(6):583-584. doi:10.1001/jamadermatol.2014.5112
Editorial

Finasteride and the Uncertainties of Establishing Harms

Abstract Full Text
JAMA Dermatol. 2015;151(6):585-586. doi:10.1001/jamadermatol.2015.37

A Reassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children

Abstract Full Text
JAMA Dermatol. 2015;151(6):587-588. doi:10.1001/jamadermatol.2014.4306
Original Investigation

Association Between Malignancy and Topical Use of Pimecrolimus

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):594-599. doi:10.1001/jamadermatol.2014.4305

According to this longitudinal cohort study, it seems unlikely that topical pimecrolimus as it was used in the Pediatric Eczema Elective Registry cohort to treat atopic dermatitis is associated with an increased risk of malignancy. See the Editorial by Hanifin.

Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis

Abstract Full Text
free access has audio
JAMA Dermatol. 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36

Available toxicity information from clinical trials of finasteride in men with androgenic alopecia (AGA) is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of AGA, most would have been excluded from the pivotal studies that supported US FDA approval for AGA. Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of AGA.

Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):607-615. doi:10.1001/jamadermatol.2014.4777

This prospective population-based cohort study found a stable 2 to 3 times elevated risk by number of previous melanomas for patients with either familial or sporadic melanoma.

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):616-622. doi:10.1001/jamadermatol.2014.5479

In a prospective observational cohort study of patients with plaque-type psoriasis, Menting et al establish a therapeutic range for adalimumab trough levels of 3.51 mg/L to 7.00 mg/L, which corresponds to an optimal clinical effect.

Frequency of Primary Nonadherence to Acne Treatment

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):623-626. doi:10.1001/jamadermatol.2014.5254

This original investigation shows that primary adherence to an acne treatment regimen is better when only 1 treatment is prescribed.

Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):627-634. doi:10.1001/jamadermatol.2014.5641

This retrospective analysis suggests that leukocyte hyperactivation may underlie cutaneous lesions in patients with PLCG2-associated antibody deficiency and immune dysregulation.

Case Report/Case Series

Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):635-637. doi:10.1001/jamadermatol.2015.0175

This case report describes the successful use of narrowband UV-B phototherapy for the treatment of sclerotic chronic cutaneous graft-vs-host-disease (GVHD). Further study should be performed to evaluate the effectiveness of this therapeutic modality for patients with sclerotic chronic cutaneous GVHD.

A Somatic p.G45E GJB2 Mutation Causing Porokeratotic Eccrine Ostial and Dermal Duct Nevus

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):638-641. doi:10.1001/jamadermatol.2014.5069

This case report shows that somatic GJB2 mutation is sufficient to cause porokeratotic eccrine ostial and dermal duct nevus.

Trichosporon inkin as an Emergent Pathogen in Patients With Severe Pemphigus

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):642-645. doi:10.1001/jamadermatol.2014.5462

This case describes opportunistic infection with Trichosporon inkin refractory to conventional antifungal treatment.

Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):646-650. doi:10.1001/jamadermatol.2015.59

This case report describes a patient with treatment-resistant mucous membrane pemphigoid and persistence of IgA-secreting B cells after rituximab therapy.

Review

Economic Burden of Psoriasis in the United States: A Systematic Review

Abstract Full Text
JAMA Dermatol. 2015;151(6):651-658. doi:10.1001/jamadermatol.2014.3593

This database study finds that the economic burden of psoriasis is substantial and significant in the United States.

JAMA Dermatology Clinicopathological Challenge

Purpuric Lesions on Acral Sites

Abstract Full Text
JAMA Dermatol. 2015;151(6):659-660. doi:10.1001/jamadermatol.2014.5198

Skin Leg Ulcer in an Immunocompromised Patient With Pseudomonas aeruginosa Sepsis

Abstract Full Text
JAMA Dermatol. 2015;151(6):661-662. doi:10.1001/jamadermatol.2014.5110

This case of a painless leg ulcer in an immunosuppressed patient with diverticulitis, a neutropenic fever, and sepsis due to multidrug-resistant Pseudomonas aeruginosa infection showed a cutaneous ulcer with a raised erythematous border and a base with purulent debris. What is your diagnosis?

Spontaneous Regression of an Infantile Scalp Tumor

Abstract Full Text
JAMA Dermatol. 2015;151(6):663-664. doi:10.1001/jamadermatol.2014.4985
Research Letter

Association of Bullous Pemphigoid and Malignant Neoplasms

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):665-667. doi:10.1001/jamadermatol.2014.5263

Colloidal Silver: Dangerous and Readily Available

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):667-668. doi:10.1001/jamadermatol.2015.120

γ-Secretase Mutation in an African American Family With Hidradenitis Suppurativa

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):668-670. doi:10.1001/jamadermatol.2014.5306

Identification of Bacterial DNA in the Peripheral Blood of Patients With Active Psoriasis

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):670-671. doi:10.1001/jamadermatol.2014.5585

A Chinese Herb, Indigo Naturalis, Extracted in Oil (Lindioil) Used Topically to Treat Psoriatic Nails: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):672-674. doi:10.1001/jamadermatol.2014.5460
Observation

Bullous Lichen Planus of the Nails

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):674-675. doi:10.1001/jamadermatol.2014.5701

Atrophoderma Vermiculatum: A Cutaneous Feature of Loeys-Dietz Syndrome

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):675-677. doi:10.1001/jamadermatol.2014.4900

Acute Onset of Acrokeratosis Paraneoplastica (Bazex Syndrome)

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):677-678. doi:10.1001/jamadermatol.2014.5622

Erythrodermic Epidermolysis Bullosa Acquisita

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):678-680. doi:10.1001/jamadermatol.2015.31
Correction

Missing Middle Initial in Author’s Name

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):680. doi:10.1001/jamadermatol.2015.0956

Incorrect Figure

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):680. doi:10.1001/jamadermatol.2015.1240

Error in Byline

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):680. doi:10.1001/jamadermatol.2015.1277

Error in Text

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):680. doi:10.1001/jamadermatol.2015.1427
Notable Notes

Moritz Kaposi

Abstract Full Text
JAMA Dermatol. 2015;151(6):622. doi:10.1001/jamadermatol.2015.106

Jonathan Hutchinson—The Eponyms Physician

Abstract Full Text
JAMA Dermatol. 2015;151(6):634. doi:10.1001/jamadermatol.2015.0325

True Colors

Abstract Full Text
JAMA Dermatol. 2015;151(6):641. doi:10.1001/jamadermatol.2015.107

Magic of the Skin

Abstract Full Text
JAMA Dermatol. 2015;151(6):645. doi:10.1001/jamadermatol.2014.5206

Archeological Sites and Dermatologic Medications: More Similar Than One May Think

Abstract Full Text
JAMA Dermatol. 2015;151(6):650. doi:10.1001/jamadermatol.2015.138

Hippocrates’ Contributions to Dermatology Revealed

Abstract Full Text
JAMA Dermatol. 2015;151(6):658. doi:10.1001/jamadermatol.2015.0201
JAMA Dermatology Patient Page

Granuloma Annulare

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):692. doi:10.1001/jamadermatol.2015.57
JAMA Dermatology Masthead

JAMA Dermatology

Abstract Full Text
free access
JAMA Dermatol. 2015;151(6):581. doi:10.1001/jamadermatol.2014.2922
×